Department of Urology, General University Hospital and 1st. Faculty of Medicine of Charles University in Prague, Czech Republic.
Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st. Faculty of Medicine of Charles University in Prague, Czech Republic.
J Pediatr Urol. 2022 Dec;18(6):846.e1-846.e6. doi: 10.1016/j.jpurol.2022.05.010. Epub 2022 May 19.
BACKGROUND/PURPOSE: The standard treatment for boys with non-syndromic cryptorchidism is an early orchidopexy. It is unclear if surgical intervention alone is enough for future fertility. Recent studies show benefit of neoadjuvant or adjuvant hormonal treatment with gonadorelin (GnRH) for spermatogonia maturation based on testicular biopsy. The aim of this prospective study was to assess the safety of this treatment in infants with undescended testis at the recommended timing of early gonadorelin administration and timing of orchidopexy.
Unilateral cryptorchid full term boys were initially examined (including hormonal, physical and ultrasound examination) at the age of 2.5-3.5 months. At 6 months of age, cryptorchidism was confirmed. Those with non-syndromic cryptorchidism and palpable or sonographically detected testis were randomly assigned into two groups: with and without intranasal gonadorelin treatment. Inclusion criteria were met by 36 boys (21 in GNRH and 15 in the control groups). The following orchidopexy was performed before 12 months of age with repeated examination at time of surgery. Penile size and testicular volume (using ultrasound) and basal serum levels of LH, FSH, testosterone, Inhibin B and AMH were recorded at age of 3.0 (mean) months and 11.0 (mean) months (date of surgery). The stimulation hormonal levels were checked during GnRH administration.
Between minipuberty (mean 3 months) and time of orchidopexy (mean 11 months of age) the penile size increased significantly and similarly in both groups. There was no significant difference in the change of the volume of descended testis between the groups nor of the volume of undescended testis. In addition, we did not find any significant difference in the change (drop) of hormonal levels of LH, FSH, Testosterone, Inhibin B and AMH (Table 1a) CONCLUSION: The neoadjuvant gonadorelin stimulation in infants with unilateral undescended testis has not shown any specific effect on the development of penile size, testicular volume and hormonal levels at time of orchidopexy in comparison with boys without stimulation, and in the mid-term, this treatment can be considered safe. Further follow-up is necessary to evaluate the long-term effect of this early treatment.
背景/目的:对于非综合征性隐睾症男孩,标准治疗方法是早期进行睾丸固定术。目前尚不清楚单纯手术干预是否足以保证未来的生育能力。最近的研究表明,基于睾丸活检,使用促性腺激素释放激素(GnRH)进行新生期或辅助性激素治疗对于精子发生成熟有益。本前瞻性研究的目的是评估在推荐的早期 GnRH 给药时间和睾丸固定术时间对未降睾丸婴儿进行这种治疗的安全性。
单侧隐睾足月男婴在 2.5-3.5 个月大时首次进行检查(包括激素、体格检查和超声检查)。在 6 个月大时,确认隐睾症。对于非综合征性隐睾症和可触及或超声检测到睾丸的婴儿,随机分为两组:接受和不接受鼻内 GnRH 治疗。36 名男孩符合纳入标准(GnRH 组 21 名,对照组 15 名)。所有婴儿均在 12 个月龄前进行睾丸固定术,并在手术时重复检查。记录阴茎大小和睾丸体积(超声)以及基础血清 LH、FSH、睾酮、抑制素 B 和 AMH 水平,分别在 3.0(平均)月龄和 11.0(平均)月龄(手术日期)时记录。在 GnRH 给药期间检查刺激激素水平。
在青春期前期(平均 3 个月)和睾丸固定术(平均 11 个月龄)之间,两组的阴茎大小均显著且相似地增加。两组下降睾丸的体积变化或未下降睾丸的体积变化无显著差异。此外,我们没有发现 LH、FSH、睾酮、抑制素 B 和 AMH 激素水平变化(下降)有任何显著差异(表 1a)。
与未接受刺激的男孩相比,单侧未降睾丸婴儿新生期 GnRH 刺激对睾丸固定术时阴茎大小、睾丸体积和激素水平的发育没有显示出任何特殊作用,在中期,这种治疗可以被认为是安全的。需要进一步随访以评估这种早期治疗的长期效果。